Clinical Trial Update: A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer [Phase 2]

View source ↗

Summary

Phase 2 single-arm study of bempegaldesleukin (NKTR-214) with nivolumab in cisplatin-ineligible, locally advanced or metastatic urothelial cancer has completed …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urinary Bladder Neoplasm
• Urothelial Carcinoma

Drugs mentioned

• bempegaldesleukin (NKTR-214) (bempegaldesleukin)
• nivolumab (nivolumab)

Snippet

Sponsor: Nektar Therapeutics | Conditions: Urinary Bladder Neoplasm, Neoplasm Metastasis | Phase 2 | Status: COMPLETED | Results posted: 2023-03-28